Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A Phase I Study of Carboplatin, Taxol[Superscript TM], Etoposide, and Cyclophosphamide (CTEC) with Filgrastim as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer (Meeting abstract)

A Phase I Study of Carboplatin, Taxol[Superscript TM], Etoposide, and Cyclophosphamide (CTEC) with Filgrastim as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer (Meeting abstract). 1999 Asco Meeting. 1999; ASCO(abstract 1417).


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.